The Natural History of Small Airways Physiology in Diseased and Healthy States
Launched by IMPERIAL COLLEGE LONDON · May 13, 2008
Trial Information
Current as of October 21, 2025
Completed
Keywords
ClinConnect Summary
Background
The main objective of this study is to measure the damage of the small airways in lung disease exploring the "silent zone" with methods that have not been used before together in the same patients. Furthermore, because this is a 4 year longitudinal study, the study team will investigate the time related changes of small airway function in lung disease and normal healthy subjects.
The study will also investigate the relationship between small airway resistance and inflammation.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • male or female, aged between 18-85 years;
- • volunteers who are able to give written informed consent Patients meeting the diagnostic criteria for asthma, COPD, ILD, CF, chronic cough.
- Exclusion Criteria:
- • upper respiratory tract infection within the previous 28 days
- • any history or evidence of renal, cardiovascular, gastrointestinal or hepatic disease
- • any history and evidence of neuropsychiatric disease
- • treatment with antibiotics within 4 weeks prior to the study
- • alcohol, drug abuse or any other condition associated with poor compliance
- • breast feeding
- • pregnancy
- • are unable to provide written informed consent
About Imperial College London
Imperial College London is a world-renowned research institution based in the United Kingdom, recognized for its commitment to advancing medical science and improving patient care through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, Imperial combines expertise across various fields, including medicine, engineering, and business, to drive breakthroughs in healthcare. The institution’s robust clinical trial programs are designed to evaluate new therapies and interventions, ensuring rigorous scientific standards and ethical practices while aiming to translate research findings into tangible benefits for patients and society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, United Kingdom
Patients applied
Trial Officials
Paolo Paredi, MD, PhD
Study Director
Airway Disease Section, National Heart and Lung Institute, Imperial College, London
Omar A Usmani, MD, PhD
Principal Investigator
Airway Disease Section, National Heart and Lung Institute, Imperial College, London
Peter J Barnes, Prof
Study Chair
Airway Disease Section, National Heart and Lung Institute, Imperial College, London
Neil Pride, Prof
Study Chair
Airway Disease Section, National Heart and Lung Institute, Imperial College, London
Michael Goldman, Prof
Study Chair
Airway Disease Section, National Heart and Lung Institute, Imperial College, London
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials